Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
8,117,644
-
Shares change
-
+2,082,781
-
Total reported value, excl. options
-
$430,405,890
-
Value change
-
+$117,389,129
-
Put/Call ratio
-
49%
-
Number of buys
-
71
-
Number of sells
-
-28
-
Price
-
$53.01
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2020
120 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8,117,644 shares
.
Largest 10 shareholders include STATE STREET CORP (974,381 shares), BlackRock Inc. (720,887 shares), Artemis Investment Management LLP (701,498 shares), VANGUARD GROUP INC (576,588 shares), ALLIANCEBERNSTEIN L.P. (504,405 shares), Avidity Partners Management LP (388,095 shares), ACUTA CAPITAL PARTNERS, LLC (340,500 shares), CITADEL ADVISORS LLC (313,962 shares), Logos Global Management LP (300,000 shares), and MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (297,245 shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.